Sigma Planning Corp cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,785 shares of the company’s stock after selling 950 shares during the period. Sigma Planning Corp’s holdings in Syndax Pharmaceuticals were worth $235,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in SNDX. Assenagon Asset Management S.A. grew its stake in shares of Syndax Pharmaceuticals by 343.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock worth $27,292,000 after purchasing an additional 1,598,428 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $15,165,000. Eventide Asset Management LLC acquired a new position in Syndax Pharmaceuticals in the third quarter valued at about $15,150,000. First Turn Management LLC grew its stake in Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after acquiring an additional 546,776 shares during the period. Finally, Sphera Funds Management LTD. grew its stake in Syndax Pharmaceuticals by 25.9% in the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock valued at $19,921,000 after acquiring an additional 212,799 shares during the period.
Syndax Pharmaceuticals Stock Performance
SNDX opened at $15.64 on Friday. Syndax Pharmaceuticals, Inc. has a 52-week low of $12.06 and a 52-week high of $25.16. The firm has a market capitalization of $1.33 billion, a PE ratio of -4.31 and a beta of 0.90. The business’s 50-day simple moving average is $14.14 and its 200 day simple moving average is $16.85.
Analyst Upgrades and Downgrades
Read Our Latest Report on Syndax Pharmaceuticals
Insider Buying and Selling
In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 13,288 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. This represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,683 shares of company stock worth $336,087. Corporate insiders own 4.10% of the company’s stock.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Further Reading
- Five stocks we like better than Syndax Pharmaceuticals
- What is MarketRank™? How to Use it
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- How to Profit From Growth Investing
- 5 Best Gold ETFs for March to Curb Recession Fears
- Following Congress Stock Trades
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.